- Home
- PEW vs MGNX Comparison
PEW vs MGNX Comparison
Compare PEW & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEW | MGNX |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 94.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PEW | MGNX |
|---|---|---|
| Price | $3.17 | $1.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $6.75 | $3.20 |
| AVG Volume (30 Days) | 527.8K | ★ 1.9M |
| Earning Date | 02-14-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $92,782,000.00 | ★ $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $0.99 |
| 52 Week High | $21.40 | $3.60 |
Technical Indicators
Market Signals| Indicator | PEW | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 69.49 |
| Support Level | $3.00 | $1.54 |
| Resistance Level | $3.26 | $1.66 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 58.33 | 90.35 |
Price Performance
Historical ComparisonAbout PEW GrabAGun Digital Holdings Inc.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.